Abstract: A compound of the formula (I): ##STR1## wherein X is --CH.sub.2 -CH.sub.2 -- or --CH.dbd.CH--,Y is ##STR2## Z is an oxygen or sulfur atom, R.sup.1 and R.sup.2 are independently a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group and ring A is an optionally substituted 6-membered homocyclic ring,or its ester or salt which is useful as an inhibitory agent for the biosynthesis of the cholesterol.

Abstract: A compound of the formula: ##STR1## wherein the dotted line represents optional unsaturation; R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, alkoxy, aralkoxy, alkanoyloxy, hydroxy, halo, amino, mono- or dialkylamino, alkanamido or sulfonamido or R.sup.1 and R.sup.2 together are methylenedioxy, ethylenedioxy or propylenedioxy; R.sup.3 is hydrogen or alkyl; n is one of the integers 2,3 or 4; X is O or NR.sup.4, in which R.sup.4 is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof, are antipsychotic agents.

Abstract: Arylalkoxycoumarins of the general formula I ##STR1## where R.sup.1 and R.sup.2 independently of one another are each hydrogen, lower alkyl, phenyl or halogen, or the two radicals together form an alkylene bridge of 3 to 5 carbon atoms, R.sup.3 is lower alkyl or halogen, n is an integer of from 0 to 3, m is an integer of from 0 to 4, R.sup.4 is hydrogen or lower alkyl and Ar is a phenyl ring which is monosubstituted to trisubstituted by halogen, C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -alkoxy or monosubstituted by nitro, cyano or trifluoromethyl or is a naphthyl ring, with the proviso that m is not 0 when Ar is unsubstituted phenyl, processes for their preparation, and drugs prepared therefrom.

Abstract: As a new antibiotic is provided a compound, now nominated as MI43-37F11 substance, which has formula ##STR1## This MI43-37F11 substance has an antitumor activity, an activity to enhance the production of interleukin-1 in vivo in a mammalian, and an activity to activate a macrophage in vivo in a mammalian. MI43-37F11 substance may be produced by cultivation of Streptoverticillium eurocidicum MI43-37F11 strain identified as FERM BP-2783.

Abstract: Isocoumarins with cationic substituents, their use in inhibiting serine proteases with trypsin-like, chymotrypsin-like and elastase-like specificity and their roles as anticoagulant agents, and anti-inflammatory agents.

Abstract: An alkoxycoumarin substituted by a heterocyclic radical, of the formula ##STR1## Het is one of the following heterocyclic radicals: where X is oxygen or sulfur.

Abstract: Optical indicator chalcogen (selenide or sulfide) compounds responsive to oxidants, e.g., hydrogen peroxide, and methods for preparing and using such indicators. Upon oxidation the resulting intermediate undergoes spontaneous elimination of the chalcogen residue to yield a signal compound which provides an optical signal such as fluorescence. Preferred fluorogenic indicator compounds are 3-chalcogen-3,4-dihydrocoumarin derivatives and 3-chalcogen-3,4-dihydro-2-quinolone derivatives. Such indicator compounds provide highly fluorescent products upon oxidation by hydrogen peroxide and are useful in analytical systems which generate hydrogen peroxide in response to the analyte under determination.

Abstract: Described is a process for preparing a racemic or chiral aryloxypropanolamine (1) or arylethanolamine (2) of the formula ##STR1## wherein Ar is aryl, substituted aryl, heteroaryl, or aralkyl and R is alkyl, substituted alkyl, aralkyl, or WB wherein W is a straight or branched chain alkylene of from 1 to about 6 carbon atoms and wherein B is --NR.sub.2 COR.sub.3, --NR.sub.2 CONR.sub.3 R.sub.4, --NR.sub.2 SO.sub.2 R.sub.3, --NR.sub.2 SO.sub.2 NR.sub.3 R.sub.4, or --NR.sub.2 COOR.sub.5, where R.sub.2, R.sub.3, R.sub.4, and R.sub.5 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, alkoxyaryl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.3 and R.sub.5 are not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.3 or --NR.sub.3 COOR.sub.5, or R.sub.3 and R.sub.4 may together with N form a 5- to 7-membered heterocyclic group.The process can be used to prepare beta-blocking agents, useful in the treatment of cardiac conditions.

Abstract: Chromogenic or fluorogenic silanes are formed in which a reactive organosilane is coupled to a chromogenic or fluorogenic nucleus of the coumarin class of compounds, by an ether, urethane or urea linkage. The preferred compounds have the general formula.X.sub.y R'.sub.z Si(CH.sub.2).sub.n L-Couwherein X is a displaceable or hydrolyzable group which allows the silanes to derivatize protic materials; R' is an aliphatic or aromatic hydrocarbon group; L is an ether (O), urethene (NCO) or urea (NCN) linkage; Cou is a coumarin derivative; n=1 to 8; y=1 to 3 and Z=0 to 2, such that y plus z equal 3. The ether linked silanes may be formed by hydrosilylation of an alkenyl ether of the coumarin compound, while the urethane or urea linked silanes may be formed by the direct reaction of a reactive silylisocyanate with a hydroxyl- or amine-substituted coumarin compound. The silanes are useful in derivatizing protic materials to provide the protic materials with chromogenic or fluorogenic properties.

Abstract: Novel tricyclic compounds having a TXA.sub.2 -antagonizing activity represented by formula (I): ##STR1## which strongly antagonize an action of thromboxane A.sub.2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.

Abstract: The present invention provides compounds of the general formula: ##STR1## wherein Ar is a substituted or unsubstituted aromatic or heteroaromatic radical, A is a straight-chained or branched alkylene chain containing up to 8 carbon atoms, a --CH.sub.2 -- group of which can be replaced by a cycloalkylene radical containing 3 to 7 carbon atoms, B is a straight-chained mono- or bicyclic, optionally branched, saturated or unsaturated alkylene chain containing up to 12 carbon atoms, a --CH.sub.2 -- group of which can be replaced by a cycloalkylene radical containing 3 to 7 carbon atoms and/or up to two --CH.sub.2 -- groups of which can be replaced by an oxygen or a sulphur atom or by an --S(.dbd.O) or --S(.dbd.O).sub.2 group, X is a valency bond, an oxygen atom or an --NR.sup.1 group, in which R.sup.1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated alkyl or nitroxyalkyl radical containing up to 6 carbon atoms or R.sup.1, together with the nitrogen atom of the --NR.sup.

Abstract: The invention relates to compounds of formula (I), some of which are derived from culture of Xenorhabdus nematophilus and Xenorhabdus luminescens. The compounds possess antibacterial, antifungal, acaricidal, anti-inflammatory and antiulcerogenic properties.

Abstract: Fluorogenic indicator compounds responsive to the presence of hydrogen peroxide and methods and test compositions for determining hydrogen peroxide in a test sample. Preferred indicator compounds are 3,4-dihydrocoumarin derivatives and 3,4-dihydro-2-quinolone derivatives, especially those having a dialkylamino group at the 7-position. Such particularly preferred compounds are of the formula: ##STR1## wherein R.sup.1 is hydrogen, cyano, or --COOR.sup.6, --CONHR.sup.6 or --CON(R.sup.6).sub.2 where R.sup.6 is hydrogen, alkyl, alkenyl, or aryl; R.sup.3 and R.sup.4 are lower alkyl; and Y is .dbd.0 or .dbd.N--R.sup.5 where R.sup.5 is hydrogen or lower alkyl. The indicator compounds yield highly fluorescent products upon oxidation by hydrogen peroxide in the presence of a peroxidatively active substance and are useful in analytical systems which generate hydrogen peroxide in response to an analyte under determination in a test sample.

Abstract: Disclosed is a three-step process for the preparation of 3-chloro-4-alkyl-7-hydroxy or alkoxycoumarin compounds starting with resorcinol or a monoalkyl ester of resorcinol and chlorinating an intermediate compound with sulfuryl chloride in the presence of acetic acid or an alkyl acetate.

Abstract: Novel asymmetric thioethers of the formula ##STR1## in which the general symbols have the following meanings: R.sup.0 represents hydrogen or C.sub.1-7 -alkanoyl,R.sup.1 represents C.sub.1-3 -alkyl which may be substituted by one or more halogen atoms having an atomic number of at most 17,R.sup.2 represents an aliphatic radical having from 5 to 15 carbon atoms,A represents ethylene, a single bond or vinylene,B.sup.1 represents C.sub.1-7 -alkylene or phenylene,B.sup.2 represents a single bond, ethylene or phenylene, andM represents an aromatic radical of the partial formula ##STR2## in which the symbols have the following meanings: R.sup.3 represents hydrogen or C.sub.1-4 -alkyl,X represents NH, O, S or if R.sup.4 represents hydrogen, a single bond,one of the symbols R.sup.4 and R.sup.5 represents hydrogen and the other represents the group --CO--R.sup.6, orR.sup.4 and R.sup.5 together represent the radical --CO--C(R.sup.6).dbd.C(R.sup.7)--or--CO--C(R.sup.7).dbd.C(R.sup.6)--orR.sup.4 R.sup.

Abstract: The invention relates to novel compounds comprising lipophilic complexes of silybin, silidianin, and silicristin with phospholipids, and the preparation of these complexes by non-conventional methods. Absorption of the novel compounds in the gastrointestinal tract is appreciably greater, resulting in higher plasma levels than for the individual flavanolignans. The resulting improvement in the pharmacokinetic and pharmacological parameters is such that the substances can advantageously be used in the treatment of acute and chronic liver disease of toxic, metabolic or infective origin or of degenerative nature.

Abstract: A compound having the formula: ##STR1## wherein R.sub.1 is halogen or a substituted or unsubstituted hydrocarbon group; R.sub.2 R.sub.6 and R.sub.7, which may be the same or different, each represents hydrogen or a substituted or unsubstituted hydrocarbon group, or R.sub.6 and R.sub.7 taken together may represent a hetero group having one or more hetero atoms; R.sub.3 and R.sub.4 which may be the same or different each represents a substituted or unsubstituted hydrocarbon group; or R.sub.3 and R.sub.4 taken together may represent an alkylene group or a hetero group having one or more hetero atoms and R.sub.5 is hydrogen, a substituted or unsubstituted hydrocarbon group, halogen or a free or protected hydroxy group, or a pharmaceutically acceptable salt thereof. The compounds have antiaggregating properties.

Abstract: Novel bicyclooxyaryl thioureas are provided together with methods for their preparation and use as the active toxicant in pesticidal compositions.

Abstract: A phosphonamidate or phosphonate analog-ligand having a conformation that substantially corresponds to the conformation of a hydrolytic transition state of an amide or ester ligand is used to produce antibodies of predetermined specificity. The antibodies include an epitope that binds to and thereby stabilizes the tetrahedral carbon atom of the amide or ester hydrolysis transition state of the ligand to hydrolyze the ligand at a predetermined site.

Abstract: Compounds of the formula ##STR1## wherein Y is ##STR2## M is hydrogen, or an alkali metal or ammonium ion, X is --O-- or an amino group,R is H, Cl, Br, CN or carbamoyl,R.sup.1 is H or --SO.sub.3 H, andA is one of several particular organic radicals,are especially useful in the photometric or fluorimetric determination of phosphatase or sulphatase activity in a liquid sample.

Abstract: Arenes, such as benzoic acid and substituted benzoic acids, are readily thallated by thallium(III) compounds such as the trifluoroacetate and subsequently reacted with palladium chloride and simple olefins, dienes, allylic halides, vinyl halides, vinyl esters, or unsaturated cyclopropanes or unsaturated cyclobutanes to give isocoumarins.

Abstract: Sulfonates of hydroxycoumarins of the formula I ##STR1## where R.sup.1 and R.sup.2 are identical or different and are each hydrogen, halogen or alkyl of 1 to 5 carbon atoms which can be substituted by --NR.sup.4 R.sup.5, --OR.sup.4 or --OC(O)R.sup.4, where R.sup.4 and R.sup.5 are identical or different and are each hydrogen or alkyl of 1 to 4 carbon atoms, or R.sup.1 and R.sup.2 are each a carboxylic acid group --OC(O)R.sup.4 or a carboxamido radical, with the proviso that R.sup.1 is not methyl when R.sup.2 is hydrogen, or R.sup.1 and R.sup.2 together form a --(CH.sub.2).sub.n -- chain where n is 3-5, and R.sup.3 is a straight-chain or branched alkyl radical of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms, each of which can be substituted by halogen, --OR.sup.4, --NR.sup.4 R.sup.5, --CN or phenyl, or R.sup.3 is a straight-chain or branched alkenyl radical of 3 to 8 carbon atoms, an amino group -- NR.sup.4 R.sup.

Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.

Abstract: This invention is a process for cyclizing an ortho-alkenyl arenol, wherein the double bond of the alkenyl moiety is one or two carbons removed from the aromatic ring, with carbon monoxide, wherein the process comprises contacting an ortho-alkenyl arenol with carbon monoxide in the presence of a catalytic amount of a catalyst comprising (1) a rhodium-carbonyl complex and (2) an amine with a pK.sub.a of 6 or greater, arsine, phosphine, stibine or mixture thereof, under conditions such that a lactone-fused aromatic compound is prepared.

Abstract: There are described novel dyes of the formulae ##STR1## in which R.sub.1 and R.sub.2 independently of one another are each hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aralkyl or aryl, and R.sub.1 and R.sub.2 together with the nitrogen atom, and optionally with the inclusion of further hetero atoms, can also form a 5- to 7-membered heterocycle, or one of the radicals R.sub.1 or R.sub.2 can be linked with the carbon atoms, in the o-position with respect to the amino group, of the ring A to form a fused-on, saturated, unsubstituted or substituted 5- or 6- membered ring,X is .dbd.NR.sub.3, .dbd.NCOR.sub.4, ##STR2## .dbd.NH or .dbd.O, wherein R.sub.3 is alkyl or unsubstituted or substituted phenyl,R.sub.4 is unsubstituted or substituted alkyl, aralkyl, aryl, vinyl, alkoxy, phenoxy or amino, andR.sub.5 is cyano, carbalkoxy, or unsubstituted or substituted carbonamide, andR.sub.

Abstract: There are described compounds of formula I, ##STR1## in which Ra, Rb, Rc, Rd, Re, Rf and Rg, which may be the same or different, each represent hydrogen, amino, hydroxy, alkoxy, alkenyloxy, halogen, acyl, alkenyl, alkyl, or alkoxy substituted by phenyl,Rh is hydrogen, alkyl or --COOH.X is a hydrocarbon chain containing from 2 to 10 carbon atoms and optionally substituted by a hydroxy group,A has no significance or represents Y, OY, or SY and Y represents a C 1 to 4 hydrocarbon chain which is optionally substituted by alkyl C 1 to 4,E and G, which may be the same or different, each represent --O--, --S-- or --CH.sub.2 --, provided that at least one of E and G is --O-- or --S--,L, together with the carbon atoms to which it is attached, forms a benzene, furan, thiophene, pyrrole, or pyran-2-one ring,and pharmaceutically acceptable derivatives thereof.

Abstract: A selective process is described for producing monohalogenated derivatives of 7-hydroxy coumarin wherein the halo substituent is at the desired position and the final product is free of other monohalogenated isomers. The resulting products and pharmaceutical compositions containing the same, especially those wherein the halo substituent is at the 8 position, have valuable specific coronary vasodilating activity.

Abstract: There are described compounds of formula I, ##STR1## in which Ra, Rb, Rc, Rd, Re, Rf and Rg, which may be the same or different, each represent hydrogen, amino, hydroxy, alkoxy, alkenyloxy, halogen, acyl, alkenyl, alkyl, or alkoxy substituted by phenyl,Rh is hydrogen, alkyl or --COOH.X is a hydrocarbon chain containing from 2 to 10 carbon atoms and optionally substituted by a hydroxy group,A has no significance or represents Y, OY, or SY and Y represents a C 1 to 4 hydrocarbon chain which is optionally substituted by alkyl C 1 to 4,E and G, which may be the same or different, each represent --O--, --S-- or --CH.sub.2 --, provided that at least one of E and G is --O-- or --S--,L, together with the carbon atoms to which it is attached, forms a benzene, furan, thiophene, pyrrole, or pyran-2-one ring,and pharmaceutically acceptable derivatives thereof.

Abstract: The present invention is directed to novel amino-substituted 2-cumaryl-3'-chromenylium salts of the general formula ##STR1## wherein R.sup.3 and R.sup.7 are a dialkyl or cycloalkyl disubstituted amino group, hydrogen, or hydroxy group, provided that at least one of R.sup.3 and R.sup.7 is an amino group, R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, and R.sup.8 are hydrogen, an alkoxy group, or two of these substituents together form an aromatic ring, provided that R.sup.1, R.sup.2 and R.sup.4 may be the same or different, and R.sup.5, R.sup.6 and R.sup.8 may be the same or different, and Y.sup.- is an acidic anion and to the process for their preparation.

Abstract: Two species of a coumarin derivative are disclosed, both of which may be produced from a 7-hydroxycoumarin precursor. The one species is an oxime and the other is a .beta.-haloallyl ester.A method for making a psoralen compound in high yield comprises treating these coumarin derivatives with an acid to fuse a furan ring thereto, and recovering a 5'-methyl psoralen therefrom. The 5'-methyl psoralen may be produced in up to about 70% overall yield with respect to the 7-hydroxycoumarin precursor.

Abstract: AI-77 compounds, pharmaceutically acceptable salts thereof, and a process for the preparation thereof are described, said compounds having the formulae ##STR1## wherein: X is NR.sub.6 or O; Y is NHR.sub.5 or combine with Z to provide a link for bonding C and C; Z is H or combines with Y to provide a link for bonding C and C; R.sub.1, R.sub.3 and R.sub.5 are each H, R', --CH.sub.2 R, or --COR; R.sub.6 is H or R; R.sub.7 is H, R or CH.sub.2 R; R is a hydrocarbon group consisting of a saturated or unsaturated straight or branched aliphatic group of C.sub.1 to C.sub.17, an aromatic group of C.sub.6 to C.sub.10, a cage type group of C.sub.7 to C.sub.10, a monocyclic aliphatic group of C.sub.3 to C.sub.8, an aromatic-aliphatic group of C.sub.7 to C.sub.15, a heterocyclic hydrocarbon of C.sub.1 to C.sub.9, wherein the above hydrocarbons can be substituted with one or more groups selected from halogen, oxo, carboxyl, hydroxyl, a saturated or unsaturated straight or branched aliphatic group of C.sub.1 to C.sub.

Abstract: This invention relates to new phenyl-alkanoic acids, their derivatives at the carboxy group, and pharmaceutically acceptable salts thereof, which have anti-inflammatory, analgesic and antipyretic activities.

Abstract: A simple, direct synthesis route is provided for Ochratoxin compounds, particularly Ochratoxin A, Ochratoxin B, and Ochratoxin C. The reaction involves treating the dimethyl ester of 2-hydroxy-4-methylbenzene-1,3-dioic acid with a deprotonating agent, followed by addition of acetaldehyde, to provide a precursor compound, which can conveniently be converted to Ochratoxins A, B or C. The synthesis route allows for the first time laboratory and industrial scale synthesis of ochratoxins A, B and C in large quantities and pure form making them available as toxins, for use as anti-toxin investigation works, and for biological activity investigations and residue studies.

Abstract: The present invention provides aryl ether derivatives of the general formula: ##STR1## wherein A is an oxygen atom or the group >N--R.sub.1, R.sub.1 being a hydrogen atom or a lower alkyl radical, R.sub.2 and R.sub.3, which can be the same or different, are hydrogen atoms or lower alkyl radicals, R.sub.4 is a hydrogen atom or a hydroxyl group, R.sub.5 is a hydrogen atom or an acyl radical, R.sub.7 is a hydrogen atom, a lower alkyl radical or a lower alkanoyl radical and R.sub.8 is a hydrogen atom, a lower alkyl radical, a lower alkoxy radical or a hydroxyl group; and the pharmacologically acceptable salts thereof.The present invention also provides a process for the preparation of these compounds and pharmaceutical compositions containing them. It is also concerned with the use of these compounds for combating allergic diseases.